Armistice Capital’s Addex Therapeutics ADXN Stock Holding History

Armistice Capital’s Portfolio ADXN Stock Details ADXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-43,000	Closed	-$260K	–	339
2023 Q4	$260K	Buy	43,000 +16,150	+60%	+$101K	﹤0.01%	223
2023 Q3	$206K	Buy	26,850 +13,650	+103%	+$138K	﹤0.01%	200
2023 Q2	$138K	Buy	+13,200	New	+$191K	﹤0.01%	185
2022 Q4	–	Sell	-16,000	Closed	-$256K	–	194
2022 Q3	$256K	Buy	16,000 +3,349	+26%	+$74.9K	﹤0.01%	160
2022 Q2	$291	Sell	12,651 -15,753	-55%	-$1.18M	0.01%	149
2022 Q1	$2.89M	Sell	28,404 -2,358	-8%	-$258K	0.06%	90
2021 Q4	$3.87M	Buy	+30,762	New	+$4.64M	0.06%	116

Other funds holding ADXN

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Armistice Capital's ADXN Position: Q1 2024 in Review

Armistice Capital sold out of Addex Therapeutics (ADXN) in Q1 2024, closing a stake of 43,000 shares — an estimated $260K sold.

Armistice Capital first reported a position in ADXN in Q4 2021 and held it in 7 quarters. The position peaked at $3.87M in Q4 2021. 1 fund tracked by Wall St. Rank holds ADXN as of Q1 2024.

Armistice Capital reported no remaining Addex Therapeutics position as of Q1 2024 after selling out during the quarter.
Armistice Capital sold 43,000 Addex Therapeutics shares in Q1 2024, an estimated $260K.
Armistice Capital first reported a position in Addex Therapeutics in Q4 2021 and held it in 7 quarters.
Armistice Capital's Addex Therapeutics position peaked at $3.87M in Q4 2021.
1 fund tracked by Wall St. Rank held Addex Therapeutics as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.